Q3 2024 MNC Earnings Recap: Johnson & Johnson Retains Top Spot, Pfizer Surges 32% to Reclaim Second Place

10Month15Johnson & Johnson announced2024In the third quarter of the year, the company achieved revenue225Billion USD, Year-over-Year Growth5 %, the first three quarters achieved revenue663USD billion, a year-on-year increase of4%. Among them, innovative drugsQ3Revenue1456USD billion, year-on-year growth6%; Medical Technology Business Revenue79USD billion, a year-on-year increase of6%. In the field of innovative drugs, oncology productsDarzalex(Daratumumab)Q3 Revenue30USD billion, a year-on-year increase of22%；Erleada(Apalutamide)Q3Revenue8USD billion, a year-on-year increase of25%。Notably, the target of the collaboration with Legend BiotechBCMA CAR-TTherapyCarvykti(Cilta-cel)Q3Revenue3Billion USD, year-on-year growth88%, becoming the product with the highest sales growth in the third quarter. Immunology productsTremfya (Guselkumab)Q3Sales Volume10USD billion, year-on-year growth13.0%. Neurology ProductsSpravato(Esketamine)Q3Revenue3USD billion, a year-on-year increase of55%. Cardiovascular ProductsOpsumit(Macitentan)Q3Revenue6Billion USD, year-on-year growth17%. The company has raised2024The growth expectation of annual revenue for the year, i.e.894Billion USD to898Billion US dollars.

10Month29Recently, Pfizer announced2024In the third quarter of the year, the company achieved revenue177.02USD billion, year-on-year growth32%, removeComirnatyAndPaxlovid, Total revenue from other products was136Billion USD, Year-on-Year Growth14%；Total income for the first three quarters was458.64Billion USD, Year-on-Year Growth2%。Paxlovid、Prevnar family、Vyndaqel family、 Eliquis(Apixaban),Ibrance(Palbociclib) Five Products inQ3Quarterly product sales are all in10Hundreds of millions of US dollars or more.In the field of oncology,Q3Income40.43RMB billion, a year-on-year increase of31% ，Ibrance The highest sales volume generated, approximately10.87Billion USD, a year-on-year decrease12%；However,Elrexfio （elranatamab）、TalzennaProducts such as (Talazoparib) have seen relatively high sales growth;Especially through acquisitionsSeagenObtainedPadcev(Vyntusumab),Adcetris(Brentuximab Vedotin),Tukysa(Tucatinib) andTivdak，Q3Cumulative revenue as high as8.35Billion US dollars.In the field of specialized nursing,Q3Income42.89USD billion, a year-on-year increase of15%。In the general nursing field,Q3Income90.6Billion USD, Year-on-Year Growth44%。Based on this, the company raised its full-year revenue guidance, i.e.610Billion USD to640Billion US dollars.

10 Month 23 Date, Roche announced2024Third Quarter Performance of the Year, Company's Revenue for the First Nine Months Approximately450million Swiss francs, a year-on-year increase of6%；Third-Quarter Sales Increase Year-over-Year9%, the growth rate remained flat with the second quarter.This growth is mainly attributed to the strong demand for new drugs and diagnostic products, particularly in the fields of immunoassays, pathology, and molecular diagnostic solutions.Among them,Q3Sales Growth in China 8%, mainly due toXofluza(Mabaloxavir),Perjeta(Pertuzumab),Polivy(Vibrotuzumab) and Avastin(Bevacizumab) and other products sales driven.In the pharmaceutical business,Q3Revenue is approximately 343 million Swiss francs, year-on-year growth7%；IncludingOcrevus(Ocrelizumab,50.56CHF billion)Hemlibra(Emicizumab,32.80CHF billion),Vabysmo(Faricimab,28.16Million Swiss Francs),Phesgo(Trastuzumab,12.44CHF billion) and Polivy（8.17million Swiss francs) and other products, with a cumulative contribution132 Sales of CHF billion.

10Month31On the same day, Merck announced2024In the third quarter of the year, the company achieved revenue166.57Billion USD, year-on-year growth7%；Revenue for the first three quarters485.44USD billion, a year-on-year increase of7%。Among them, the pharmaceuticals business inQ3Income149.43Billion USD, Year-on-Year Growth8%；China RegionQ3Income9.96Billion USD, accounting for a proportion of global pharmaceutical business revenue6.7%。Among them,Keytruda(Pembrolizumab)Q3Sales amount to74.29Billion USD, Year-on-Year Growth21%, with cumulative sales in the first three quarters reaching216.46Billion USD, Year-on-Year Growth18%, thanks to its application in triple-negative breast cancer (TNBC), Renal Cell Carcinoma (RCC) and non-small cell lung cancer (NSCLC) and other early-stage tumor indications;Not only that, but clinical trials for early-stage cancer indications such as locally advanced head and neck squamous cell carcinoma in the perioperative period are expected to further expand the market.In addition,HPVVaccineGardasil/Gardasil 9The sales volume is23.06Billion USD, a year-on-year decrease10%, primarily due to the decrease in demand in the Chinese market, which nearly offset the double-digit growth in all other regions.In addition, pneumococcal conjugate vaccineCapvaxiveWill collaborate with PfizerPrevnar 20The vaccine rollout began, with the vaccine having been 2024 Year 6 Month Obtained FDA Approval,CDCLast Week's Suggestions 50 For use by adults aged and above.Despite includingKeytrudaDespite strong sales growth of its domestically produced products, Merck still lowered its full-year revenue guidance, with expected revenue at636Hundred Million~641Between billion US dollars.

10Month30Day, AbbVie announced2024In the third quarter of the year, the company achieved revenue144.60Billion USD, year-on-year growth3.8%。In terms of business segments, autoimmune, oncology, neuroscience, and aesthetics contributed respectively.70.46Billion USD (+3.9%）、16.87Billion US dollars (+11.6%）、23.63Billion USD (+15.6%）、12.39Billion US dollars (-0.1%）。In the first three quarters, the company's total revenue412.32Billion USD, Year-on-Year Growth4.1%。In the autoimmune field, due to the impact of biosimilars, the sales revenue of Humira (Adalimumab)22.27Billion USD, a year-on-year decrease36.5%；Skyrizi(Lisencekimab) andRinvoq(Upadacitinib) sales were respectively32.05Billion USD and16.14USD billion, year-on-year growth51.5%And47.4%。In the field of oncology,Imbruvica(Ibrutinib) Sales8.28Billion USD, a year-on-year decrease8.8%；Venclexta(Venetoclax) Sales6.77USD billion, a year-on-year increase of18.2%；TargetedFRα ADCDrugElahere(Somtuzumab) Sales Revenue1.39Billion USD, New TypeCD3/CD20Dual AntibodyEpkinly（epcoritamab) Sales4300Million USD.In the field of neurology,Vraylar(Cariprazine) Sales8.75Billion USD, year-on-year growth16.6%；BotoxSales Revenue8.48Billion USD, Year-over-Year Growth14.4%。The company raised its full-year revenue guidance.

11Month12Date: AstraZeneca announced2024Third Quarter Performance of the Year, First Three Quarters of the Company (9M 2024) Total Revenue391.82USD billion, a year-on-year increase of19%, wherein product revenue375.76USD billion, a year-on-year increase of19%。Q3 Quarterly Revenue135.65Billion USD, Year-on-Year Growth21%, wherein product revenue129.47Billion USD, year-on-year growth20%Revenue in China for the First Three Quarters50.49Billion USD. Single-quarter revenue in China16.71Billion USD, Year-on-Year Growth15%. The year-on-year income of the United States, Europe, and emerging countries are respectively+23%、15%、22%。2024Q3, Tumors, Vascular Metabolism, and Kidneys (CVRM), Respiratory and Immunology (R&I), Vaccines and Immunotherapy (V&I), Revenue from rare diseases were respectively55.69Billion USD (+22%）、31.59Billion USD (+20%）、19.59Billion USD (+29%）、4.6Billion US dollars (+49%）、21.48Billion USD (+11%）。

10Month25Date, Sanofi announced2024In the third quarter of the year, the company achieved revenue134.38EUR billion, a year-on-year increase of15.7%; including pharmaceuticals revenue83.65EUR billion, a year-on-year increase of13.0%; Vaccine Sector Revenue38.02Hundred MillionEuro,Year-on-year growth25.5%; Consumer Health Revenue12.71EUR billion, a year-on-year increase of7.9%, has been confirmed no later than2025The second quarter of the year was spun off from Sanofi. Among them,Dupixent(Dupilumab) driven by the continued strong demand in approved indications such as atopic dermatitis and asthma,Q3Sales34.76Million euros, a significant increase year-on-year24%; With more3Positive data from Phase III clinical trials and more indications approved, the company expectsDupixentWill arrive2030Annual long-term growth maintained at double digits. Long-actingRSVAntibodyBeyfortus Q3Sales reached6.45EUR billion, a year-on-year increase of approximately382%, not only driving up the performance of the vaccine sector, but also boosting the company's overall sales growth. In addition, revenue from newly launched drugs7.27EUR billion, a year-on-year increase of67.1%, mainly due to hemophilia therapyALTUVIIIO（+278.3%), Pompe disease enzyme replacement therapyNexviazyme/Nexviadyme（+53.6%) and other products drive.

10Month29Recently, Novartis announced2024In the third quarter of the year, the company achieved revenue128Billion dollars, exceeding market expectations118billion US dollars, increased from the same period last year10%(Calculated at fixed exchange rates); Total Net Revenue of the Company32 billion dollars, increased compared to the same period last year121%. Among which, the core business revenue51 Billion USD, Year-on-Year Growth20%, mainly due toEntresto (+26%)、Cosentyx (+28%)、Kisqali (+43%)、Kesimpta (+28%)、Pluvicto (+50%) And Leqvio (+119%)The growth in sales volume of products such as... Based on the aforementioned growth, the company has once again raised its...2024Annual performance guidance: Core operating profit for this year is currently expected to achieve high double-digit growth, while sales are projected to achieve low double-digit growth. The company stated that it is on track to...2023-2028Year Achievement+5%The compound annual growth rate of sales, to2027Achieve Core Operating Profit Margin in Year+40%The goal.

10Month31Day, Bristol-Myers Squibb (BMS) Publish2024In the third quarter of the year, the company achieved revenue of 119 Billion USD, Year-over-Year Growth 8%; Total revenue for the first three quarters359.58USD billion, a year-on-year increase of7%; R&D investment79.68Billion USD, year-on-year growth17%Among them, the oncology, hematology, and cardiovascular diseases businesses are the company's main sources of revenue, contributing respectively101.65Billion US dollars,102.55Billion USD and105.17billion dollars, accounting for a proportion of86%. In the field of oncology,Opdivo(Nivolumab) remains the primary contributor to the oncology business revenue,Q3Sales are approximately23.6billion dollars, and its subcutaneous injection formulation will be launched in the fourth quarter of this year.FDAThe approval decision;Yervoy(Ipilimumab)Q3Sales Revenue6.42Billion USD, maintaining steady growth;Opdualag(Nivolumab+RelatlimabQ3Sales are approximately2.33billion dollars, is expected to further capture market share as a standard treatment regimen for first-line treatment of melanoma. In the field of hematology,Revlimid(Lenalidomide) andPomalyst/Imnovid(Pomalidomide) Accumulated Contribution71.56Billion dollars in revenue,CD19 CAR-TTherapyBreyanzi（lisocabtagene maraleucel) inQ3Sales up to2.24Billion US dollars,Reblozyl(Roxadustat) inQ3Sales are approximately4.47Billion USD; In the cardiovascular field,Eliquis(Apixaban) inQ3Sales also reached10Hundreds of millions of US dollars or more.

10Month30Date, Eli Lilly announcedFinancial Results for the Third Quarter of 2024: The Company Achieved Revenue114.4USD billion, a year-on-year increase of20%, slightly lower thanMarket Expectations121.8Billion USD; Revenue for the first three quarters315Billion USD, Year-on-Year Growth27%。Among them, two products of tirzepatide (MounjaroAndZepbound) Become the main sales driver for Eli Lilly,Q3QuarterMounjaroRevenue31Billion US dollars,ZepboundRevenue13billion US dollars, apart from this,Taltz(Ixekizumab),Humalog(Insulin Lispro),Verzenio(Abemaciclib) Sold Separately8.8Billion USD and5.35Billion US dollars,13.7billion dollars, contributing to a significant increase. Currently, the company is still continuously expanding its production capacity to increaseMounjaroAndZepboundOutput. In the latest quarterly report, Eli Lilly lowered its revenue forecast to a maximum of460Billion US dollars.

On November 12, Bayer announced its financial results for the third quarter of 2024, with the company achieving revenue of 9.97 billion euros.Compared to the decline3.6%, lower than expected101.5Hundreds of millions of euros. However, due to the company's new drugNubeqa(Darolutamide, Year-over-Year Growth83.2%) and renal disease treatment drugsKerendia(Finerenone, Year-on-Year Growth96.4%) The strong sales performance may place the growth rate of pharmaceuticals business sales within the guidance range.3%This is the highest end. Besides, ophthalmic drugs Eylea(Year-on-year growth8.6%), Pulmonary Hypertension Treatment Drugs Adempas(Year-on-year growth9.8%) and other product sales, especially with strong growth in the United States.

10Month30Day, GlaxoSmithKline (GSK) Announced2024In the third quarter of the year, the company's revenue reached80.12Billion pounds (approximately104.96USD billion), year-on-year growth2%(Calculated at fixed exchange rates, same below). Sales in the first three quarters were232.59 Billion pounds (approximately304.69 USD billion), a year-on-year increase of8%Among them, vaccine sales declined. 15%, and specialty drugs (including oncology,HIV, Breathing/Sales of immunology products and general medicines increased respectively 19% And 7%. Affected Zantac Litigation-related allegations impact (withZantacThe costs related to reconciliation are 18 Billion Pounds),GSKTotal operating profit decreased. 86%. But reiterated the expectation: full-year revenue growth is expected. 7% To 9%, Core operating profit growth11%To 13%, Core Earnings Per Share Growth 10% To 12%. In addition, respiratory syncytial virus (RSV) Due to the impact of weak demand for shingles vaccines, the company lowered its forecast for the year on Wednesday for the second time. 2024 Annual Vaccine Sales Forecast.2024 Vaccine sales will decrease by a single-digit percentage this year. Previously, the company expected this business to grow by a low-to-mid single-digit percentage.

11Month6Date, Novo Nordisk announced2024Q3Performance, with revenue in the first three quarters2047.2Million Danish Kroner (294.6USD billion), a year-on-year increase of24%(Calculated at fixed exchange rates, the same below); Operating profit916.02Million Danish kroner, year-on-year growth22%; Net Profit727.58Million Danish Kroner. Sales of diabetes and obesity care businesses have increased 25%(In Danish kroner) to1918Million Danish Kroner, mainly due toGLP-1 (Including Semaglutide, Liraglutide) Diabetes Sales Increased 25%, Sales in the obesity care business have grown 44%, with their sales reaching respectively 1069.5Million Danish Kroner and437 Million Danish Kroner. Sales of rare disease drugs grew3%To129.34Million Danish kroner. It is worth mentioning that the weight-loss version of SemaglutideWegovy Revenue climbed to 173 Million Danish Kroner (25 billion USD), higher than the average analyst expectation of 156 Million Danish Kroner. Semaglutide has accumulated revenue in the first three quarters1412.13Million Danish Kroner (approximately203billion USD), combined with Novo Nordisk's expansion and strong ongoing momentum, surpassingKPharmaceuticals (First Three Quarters)216billion) is only half a step away. In addition, Novo Nordisk narrowed its full-year sales and profit forecast. For 2024 For the entire year's sales, Novo Nordisk's expected growth rate is 23%-27%(The previously predicted growth rate was 22% To 28%), while the operating profit growth rate is 21%-27%(The previously predicted growth rate was 20% To 28%）。

References

1, Each company's official website

2、GBIHealth, PharmaCube,InsightDatabase, Medical Colleagues, Huayi Wen Essays,bioSeedinBioSpark

"Views"Click once